Clinical Trial Update: A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076. [Phase 2]

View source ↗

Summary

Novartis conducted a Phase 2 trial of QBM076 in chronic obstructive pulmonary disease to assess safety, tolerability, and efficacy; the study was terminated and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QBM076

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COPD | Phase 2 | Status: TERMINATED | Results posted: 2016-03-24